Seer (SEER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Jun, 2026Executive summary
The annual meeting is scheduled for July 28, 2026, with voting on four key proposals, including director elections, auditor ratification, executive compensation, and the Tax Benefit Preservation Plan.
The board recommends voting only for its seven director nominees and all other proposals, emphasizing the importance of using the BLUE proxy card due to a contested election with the Radoff-JEC Group.
The Radoff-JEC Group, an activist investor group, has nominated three alternative directors and made multiple unsolicited acquisition proposals, all of which the board rejected as undervaluing the company.
The company has implemented a Tax Benefit Preservation Plan to protect significant tax assets and has repurchased shares to return capital to shareholders.
Voting matters and shareholder proposals
Proposal 1: Election of seven directors for a one-year term.
Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Proposal 3: Non-binding advisory vote on named executive officer compensation.
Proposal 4: Ratification of the Tax Benefit Preservation Plan through February 25, 2029.
The board opposes the Radoff-JEC Group’s nominees and urges shareholders not to use the white proxy card.
Board of directors and corporate governance
The board consists of seven members, five of whom are independent under Nasdaq standards.
Committees include audit, talent and compensation, corporate governance and nominating, and science and technology.
The board has a Lead Independent Director and emphasizes diversity of skills and experience.
Director compensation includes cash and equity, with annual reviews and limits on total compensation.
Stockholder recommendations for director nominations are considered if ownership and tenure thresholds are met.
Latest events from Seer
- Board urges support for its nominees to protect long-term value and resist dissident takeover.SEER
Proxy filing14 Jul 2026 - Board recommends voting for its nominees to ensure long-term value and strategic continuity.SEER
Proxy filing14 Jul 2026 - Rapid innovation, global expansion, and strong financials drive leadership in unbiased proteomics.SEER
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - 2025 revenue is guided to grow 24% amid strong adoption, innovation, and robust cash reserves.SEER
Q4 20248 Jul 2026 - Q2 revenue fell 23% to $3.1M; guidance cut and $3.7M in shares repurchased amid headwinds.SEER
Q2 20248 Jul 2026 - Vote for the seven incumbent directors to protect long-term value and strategic direction.SEER
Proxy filing8 Jul 2026 - Board urges support for incumbent directors to ensure expertise and long-term value creation.SEER
Proxy filing8 Jul 2026 - Shareholders are urged to support the current board, emphasizing innovation and disciplined governance.SEER
Proxy filing6 Jul 2026 - Board urges shareholders to reject activist nominees and support long-term value creation.SEER
Proxy filing6 Jul 2026 - Chair and CEO proposes to acquire all Class A shares for $2.45 plus contingent value rights.SEER
Proxy filing6 Jul 2026